The Lancet Infectious Diseases:DSM265用于恶性疟疾的药物预防

2017-03-29 MedSci MedSci原创

400mg单剂量的DSM265对于疟疾的预防是安全有效的

DSM265是一个实验性,选择性疟原虫二氢乳酸脱氢酶抑制剂,在体外试验中对肝-血液阶段的恶性疟原虫有良好的抑制活性。研究人员开展了DSM265对控制人类疟疾感染预防作用的临床I期试验,其结果发表于近日的The Lancet Infectious Diseases。

研究招募了,健康的、未有疟原虫感染的成年志愿者。在静脉接种3200单位的恶性疟原虫孢子前1天(第1A组)或前7天(第2组)接受的400mg DSM265或者安慰剂;另一组(第1B组),先接受9天每天250 mg的阿托伐醌和100mg氯胍持续治疗之后接种疟原虫孢子。试验的主要考察血涂片疟原虫检测阳性与接种后时间的关系。

研究共招募了22名志愿者,在第1A组中,有5人接受DSM265,2人接受安慰剂;第1B组6人接受阿托伐醌和氯胍;第2组中有6人接受DSM265,2人接受安慰剂。结果表明:第1A组和第1B组所有接受药物的志愿者都没有被感染,而服用安慰剂的2位志愿者在第11天和14天发病;第2组中有3名服药志愿者在第11,13,24天疟原虫检测阳性,另外3人弱阳性,而服用安慰剂的2位志愿者在第11天发病。几乎没有治疗相关的副作用,仅有1人出现短暂的中度血清胆红素升高。

研究表明,在接种疟原虫孢子的前1天接受400mg单剂量的DSM265对于疾病的预防是安全有效的,未来将进一步的研究DSM265对疟疾的预防应用。

原文出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1769412, encodeId=cee81e69412bb, content=<a href='/topic/show?id=172d5292332' target=_blank style='color:#2F92EE;'>#恶性疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52923, encryptionId=172d5292332, topicName=恶性疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a1b38038908, createdName=yxch49, createdTime=Tue Feb 13 20:55:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707645, encodeId=27d11e076459e, content=<a href='/topic/show?id=5e2762912b' target=_blank style='color:#2F92EE;'>#DSM265#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6291, encryptionId=5e2762912b, topicName=DSM265)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebc131440567, createdName=124987e8m17暂无昵称, createdTime=Tue Jul 18 13:55:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012187, encodeId=8f25201218ee5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 10 13:55:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541703, encodeId=f75a1541e0340, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542208, encodeId=7ae1154220819, content=<a href='/topic/show?id=d20a8e9073e' target=_blank style='color:#2F92EE;'>#药物预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87907, encryptionId=d20a8e9073e, topicName=药物预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e3b13370459, createdName=ms6829001416292975, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569699, encodeId=849115696991c, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828836, encodeId=81611828836a9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Oct 28 11:55:00 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1769412, encodeId=cee81e69412bb, content=<a href='/topic/show?id=172d5292332' target=_blank style='color:#2F92EE;'>#恶性疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52923, encryptionId=172d5292332, topicName=恶性疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a1b38038908, createdName=yxch49, createdTime=Tue Feb 13 20:55:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707645, encodeId=27d11e076459e, content=<a href='/topic/show?id=5e2762912b' target=_blank style='color:#2F92EE;'>#DSM265#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6291, encryptionId=5e2762912b, topicName=DSM265)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebc131440567, createdName=124987e8m17暂无昵称, createdTime=Tue Jul 18 13:55:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012187, encodeId=8f25201218ee5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 10 13:55:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541703, encodeId=f75a1541e0340, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542208, encodeId=7ae1154220819, content=<a href='/topic/show?id=d20a8e9073e' target=_blank style='color:#2F92EE;'>#药物预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87907, encryptionId=d20a8e9073e, topicName=药物预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e3b13370459, createdName=ms6829001416292975, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569699, encodeId=849115696991c, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828836, encodeId=81611828836a9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Oct 28 11:55:00 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1769412, encodeId=cee81e69412bb, content=<a href='/topic/show?id=172d5292332' target=_blank style='color:#2F92EE;'>#恶性疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52923, encryptionId=172d5292332, topicName=恶性疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a1b38038908, createdName=yxch49, createdTime=Tue Feb 13 20:55:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707645, encodeId=27d11e076459e, content=<a href='/topic/show?id=5e2762912b' target=_blank style='color:#2F92EE;'>#DSM265#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6291, encryptionId=5e2762912b, topicName=DSM265)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebc131440567, createdName=124987e8m17暂无昵称, createdTime=Tue Jul 18 13:55:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012187, encodeId=8f25201218ee5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 10 13:55:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541703, encodeId=f75a1541e0340, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542208, encodeId=7ae1154220819, content=<a href='/topic/show?id=d20a8e9073e' target=_blank style='color:#2F92EE;'>#药物预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87907, encryptionId=d20a8e9073e, topicName=药物预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e3b13370459, createdName=ms6829001416292975, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569699, encodeId=849115696991c, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828836, encodeId=81611828836a9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Oct 28 11:55:00 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1769412, encodeId=cee81e69412bb, content=<a href='/topic/show?id=172d5292332' target=_blank style='color:#2F92EE;'>#恶性疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52923, encryptionId=172d5292332, topicName=恶性疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a1b38038908, createdName=yxch49, createdTime=Tue Feb 13 20:55:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707645, encodeId=27d11e076459e, content=<a href='/topic/show?id=5e2762912b' target=_blank style='color:#2F92EE;'>#DSM265#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6291, encryptionId=5e2762912b, topicName=DSM265)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebc131440567, createdName=124987e8m17暂无昵称, createdTime=Tue Jul 18 13:55:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012187, encodeId=8f25201218ee5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 10 13:55:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541703, encodeId=f75a1541e0340, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542208, encodeId=7ae1154220819, content=<a href='/topic/show?id=d20a8e9073e' target=_blank style='color:#2F92EE;'>#药物预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87907, encryptionId=d20a8e9073e, topicName=药物预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e3b13370459, createdName=ms6829001416292975, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569699, encodeId=849115696991c, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828836, encodeId=81611828836a9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Oct 28 11:55:00 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
    2017-03-31 Tamikia
  5. [GetPortalCommentsPageByObjectIdResponse(id=1769412, encodeId=cee81e69412bb, content=<a href='/topic/show?id=172d5292332' target=_blank style='color:#2F92EE;'>#恶性疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52923, encryptionId=172d5292332, topicName=恶性疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a1b38038908, createdName=yxch49, createdTime=Tue Feb 13 20:55:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707645, encodeId=27d11e076459e, content=<a href='/topic/show?id=5e2762912b' target=_blank style='color:#2F92EE;'>#DSM265#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6291, encryptionId=5e2762912b, topicName=DSM265)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebc131440567, createdName=124987e8m17暂无昵称, createdTime=Tue Jul 18 13:55:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012187, encodeId=8f25201218ee5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 10 13:55:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541703, encodeId=f75a1541e0340, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542208, encodeId=7ae1154220819, content=<a href='/topic/show?id=d20a8e9073e' target=_blank style='color:#2F92EE;'>#药物预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87907, encryptionId=d20a8e9073e, topicName=药物预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e3b13370459, createdName=ms6829001416292975, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569699, encodeId=849115696991c, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828836, encodeId=81611828836a9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Oct 28 11:55:00 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1769412, encodeId=cee81e69412bb, content=<a href='/topic/show?id=172d5292332' target=_blank style='color:#2F92EE;'>#恶性疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52923, encryptionId=172d5292332, topicName=恶性疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a1b38038908, createdName=yxch49, createdTime=Tue Feb 13 20:55:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707645, encodeId=27d11e076459e, content=<a href='/topic/show?id=5e2762912b' target=_blank style='color:#2F92EE;'>#DSM265#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6291, encryptionId=5e2762912b, topicName=DSM265)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebc131440567, createdName=124987e8m17暂无昵称, createdTime=Tue Jul 18 13:55:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012187, encodeId=8f25201218ee5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 10 13:55:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541703, encodeId=f75a1541e0340, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542208, encodeId=7ae1154220819, content=<a href='/topic/show?id=d20a8e9073e' target=_blank style='color:#2F92EE;'>#药物预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87907, encryptionId=d20a8e9073e, topicName=药物预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e3b13370459, createdName=ms6829001416292975, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569699, encodeId=849115696991c, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828836, encodeId=81611828836a9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Oct 28 11:55:00 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
    2017-03-31 dongjia2015
  7. [GetPortalCommentsPageByObjectIdResponse(id=1769412, encodeId=cee81e69412bb, content=<a href='/topic/show?id=172d5292332' target=_blank style='color:#2F92EE;'>#恶性疟疾#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52923, encryptionId=172d5292332, topicName=恶性疟疾)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5a1b38038908, createdName=yxch49, createdTime=Tue Feb 13 20:55:00 CST 2018, time=2018-02-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707645, encodeId=27d11e076459e, content=<a href='/topic/show?id=5e2762912b' target=_blank style='color:#2F92EE;'>#DSM265#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6291, encryptionId=5e2762912b, topicName=DSM265)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebc131440567, createdName=124987e8m17暂无昵称, createdTime=Tue Jul 18 13:55:00 CST 2017, time=2017-07-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2012187, encodeId=8f25201218ee5, content=<a href='/topic/show?id=7d69598468' target=_blank style='color:#2F92EE;'>#Dis#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5984, encryptionId=7d69598468, topicName=Dis)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c689267, createdName=cmj8wellington, createdTime=Wed Jan 10 13:55:00 CST 2018, time=2018-01-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541703, encodeId=f75a1541e0340, content=<a href='/topic/show?id=d6e6599e27' target=_blank style='color:#2F92EE;'>#Diseases#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5997, encryptionId=d6e6599e27, topicName=Diseases)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=474713318057, createdName=Tamikia, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1542208, encodeId=7ae1154220819, content=<a href='/topic/show?id=d20a8e9073e' target=_blank style='color:#2F92EE;'>#药物预防#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87907, encryptionId=d20a8e9073e, topicName=药物预防)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7e3b13370459, createdName=ms6829001416292975, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1569699, encodeId=849115696991c, content=<a href='/topic/show?id=49e0161680c' target=_blank style='color:#2F92EE;'>#SES#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16168, encryptionId=49e0161680c, topicName=SES)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6fc215562628, createdName=dongjia2015, createdTime=Fri Mar 31 01:55:00 CST 2017, time=2017-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1828836, encodeId=81611828836a9, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Sat Oct 28 11:55:00 CST 2017, time=2017-10-28, status=1, ipAttribution=)]
    2017-10-28 howi